COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

THURSDAY, AUGUST 10, 1967

U.S. SENATE,
MONOPOLY SUBCOMMITTEE OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 10:10 a.m., in room 318, Old Senate Office Building, Senator Gaylord P. Nelson (chairman of the subcommittee) presiding.

Present: Senators Nelson, Scott, Javits, and Hatfield.

Also present: Benjamin Gordon, staff economist; Susan H. Hewman, research assistant; and William B. Cherkasky, legislative director, staff of Senator Nelson.

Senator NELSON. The committee will come to order.

Our witness today is Dr. James L. Goddard, Commissioner of the Food and Drug Administration, U.S. Department of Health, Education, and Welfare.

Dr. Goddard, the committee is grateful that you were willing to come here today to give your constructive and valuable testimony. You may proceed in any way you see fit. I assume you have no objection to my interrupting from time to time with questions.

STATEMENT OF DR. JAMES L. GODDARD, COMMISSIONER OF THE FOOD AND DRUG ADMINISTRATION, U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE, ARLINGTON, VA.; ACCOMPANIED BY WILLIAM W. GOODRICH, GENERAL COUNSEL; DR. HERBERT L. LEY, DIRECTOR, BUREAU OF MEDICINE; ALFRED BARNARD, DIRECTOR, BUREAU OF REGULATORY COMPLIANCE; AND DR. DANIEL BANES, ACTING DIRECTOR, DIVISION OF PHARMACEUTICAL SCIENCE

Dr. GODDARD. Not at all. We are pleased to be here today.

Accompanying me are William Goodrich, general counsel; Dr. Herbert Ley, Director of the Bureau of Medicine; Mr. Alfred Barnard, Director of the Bureau of Regulatory Compliance; and Dr. Daniel Banes, who heads our Division of Pharmaceutical Science.

We appreciate this opportunity to appear before you and comment on the drug questions this committee is considering. It has been several years since the Senate has considered in such depth the relationship between the pharmaceutical industry, those who prescribe and those who use drug products. Since this relationship—at this time, so closely bound together by new Federal and State health programs—is of principal interest to the Food and Drug Administration, my staff and I are most pleased to appear before you this morning.